Search Results

Alexandria Forbes/Getty Images, modified by Nicole

Business

The Many Lives of Alexandria Forbes

The MeiraGTx founder and CEO, now on her third career, didn’t take a typical path.

October 11, 2023

·

4 min read

·

Nadia Bey

Deals

MeiraGTx Files for an $86 Million IPO

MeiraGTx has filed with the U.S. Securities and Exchange Commission (SEC) its intentions to launch an initial public offering (IPO).

May 15, 2018

·

2 min read

·

Mark Terry

Deals

Gene Therapy Company MeiraGTx Buys Vector Neurosciences for Its Phase II Parkinson’s Product

MeiraGTx, headquartered in London, UK, acquired Vector Neurosciences in an all-stock deal. As part of the deal, MeiraGTx picks up Vector’s Phase II gene therapy program for Parkinson’s disease.

October 9, 2018

·

2 min read

·

Mark Terry

Courtesy of Sundry Photography/Getty Images

Business

Janssen and MeiraGTx Sign $440 Million Deal to Develop Gene Therapies for Eye Diseases

Janssen Pharmaceutical, a Johnson & Johnson company, inked a worldwide collaboration and license deal with MeiraGTx to develop, manufacture and commercialize a portfolio of drugs for inherited retinal diseases.

January 31, 2019

·

2 min read

·

Mark Terry

Business

Janssen Enters Worldwide Collaboration and License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseases

The Janssen Pharmaceutical Companies of Johnson & Johnson announced a worldwide collaboration and license agreement with MeiraGTx Holdings plc.

January 31, 2019

·

5 min read

MeiraGTx Receives EMA PRIME Designation for Achromatopsia Gene Therapy Candidate

MeiraGTx, a London and New York based gene therapy company, announced today the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to MeiraGTx’s gene therapy product candidate A002 for the treatment of patients with achromatopsia (ACHM) due to mutations in the CNGB3 gene.

March 2, 2018

·

4 min read

Business

MeiraGTx Announces Gene Therapy Manufacturing Collaboration With Oxford Genetics

The collaboration will enable MeiraGTx and Oxford Genetics to develop novel AAV vectors, as well as packaging and producer cell lines to support the manufacturing needs of MeiraGTx’s pipeline of gene therapy product candidates.

December 19, 2017

·

3 min read

Business

Oxford Genetics Announces Adeno-Associated Virus Collaboration With MeiraGTx

The collaboration will enable Oxford Genetics and MeiraGTx to develop novel AAV vectors, as well as packaging and producer cell lines.

December 5, 2017

·

2 min read

FDA

MeiraGTx Announces AAV-RPGR Granted Fast Track Designation by U.S. FDA for Treatment of X-Linked Retinitis Pigmentosa Due to RPGR Deficiency

MeiraGTx Limited, a vertically integrated, clinical stage gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for AAV-RPGR for the treatment of X-linked retinitis pigmentosa (XLRP) due to defects in the retinitis pigmentosa GTPase regulator (RPGR) gene.

April 23, 2018

·

3 min read

Drug Development

MeiraGTx Earns EMA PRIME Designation for Achromatopsia Gene Therapy Candidate

A new gene therapy to treat a debilitating eye disorder is one step closer to regulatory approval in Europe.

March 2, 2018

·

2 min read

·

Alex Keown